EPS for Theratechnologies Inc. (TH) Expected At $-0.04

March 14, 2018 - By Hazel Jackson

 EPS for Theratechnologies Inc. (TH) Expected At $ 0.04

Analysts expect Theratechnologies Inc. (TSE:TH) to report $-0.04 EPS on April, 5.They anticipate $0.01 EPS change or 33.33 % from last quarter’s $-0.03 EPS. After having $-0.06 EPS previously, Theratechnologies Inc.’s analysts see -33.33 % EPS growth. The stock increased 0.72% or $0.07 during the last trading session, reaching $9.86. About 313,797 shares traded or 119.45% up from the average. Theratechnologies Inc. (TSE:TH) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Theratechnologies Inc. (TSE:TH) Ratings Coverage

Among 2 analysts covering Theratechnologies Inc. (TSE:TH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theratechnologies Inc. had 6 analyst reports since February 25, 2016 according to SRatingsIntel. National Bank Canada downgraded Theratechnologies Inc. (TSE:TH) on Friday, November 11 to “Outperform” rating.

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. The company has market cap of $739.27 million. The Company’s lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. It currently has negative earnings.

More important recent Theratechnologies Inc. (TSE:TH) news were published by: Bioworld.com which released: “Theratechnologies, Taimed get FDA nod, and several firsts, for HIV drug” on March 08, 2018, also Seekingalpha.com published article titled: “Theratechnologies Has An Unheralded Blockbuster”, Marketwired.com published: “Theratechnologies Announces Financial Results for Second Quarter of 2017” on July 12, 2017. More interesting news about Theratechnologies Inc. (TSE:TH) was released by: Marketwired.com and their article: “Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results …” with publication date: January 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.